We are live on ! Find out more
DCOY

Decoy Therapeutics
DCOY

16 hedge funds and large institutions have $671K invested in Decoy Therapeutics in 2022 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% less ownership

Funds ownership: 0% → 0% (-0%)

16% less funds holding

Funds holding: 19 → 16 (-3)

22% less capital invested

Capital invested by funds: $859K → $671K (-$188K)

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 3

Holders
16
Holders Change
-3
Holders Change %
-15.79%
% of All Funds
0.27%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
2
Reduced
3
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$22.7K
2
HKAM
Horizon Kinetics Asset Management
New York
+$7.56K

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$45.4K
2
Millennium Management
Millennium Management
New York
-$37.8K
3
Citadel Advisors
Citadel Advisors
Florida
-$35K
4
VF
Virtu Financial
New York
-$17K
5
TRCT
Tower Research Capital (TRC)
New York
-$7.56K

DCOY Hedge Fund Activity: Q3 2022 in Review

16 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Decoy Therapeutics (DCOY) for Q3 2022, worth a combined $671K — down 22% from $859K a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of DCOY and 0 opened new positions — a net loss of 3 holders — while 3 trimmed existing stakes and 2 added.

The largest buyer was Renaissance Technologies, adding an estimated $22.7K. The largest seller was Vanguard Group, cutting an estimated $45.4K.

  • 16 institutional investors held Decoy Therapeutics (DCOY) as of Q3 2022, down from 19 in Q2 2022.
  • Funds reported $671K of Decoy Therapeutics stock for Q3 2022, down 22% quarter-over-quarter.
  • 0 funds opened new Decoy Therapeutics positions in Q3 2022 and 3 closed out, a net change of -3 holders.
  • The largest Decoy Therapeutics buyer in Q3 2022 was Renaissance Technologies, an estimated $22.7K added.
  • The largest Decoy Therapeutics seller in Q3 2022 was Vanguard Group, an estimated $45.4K sold.

Based on aggregated 13F filings for Q3 2022.